Keywords: euflexxa, cost-effective, extending, qalys, ferring, pharmaceuticals, presented

Euflexxa "cost-effective" at extending QALYs

Article | 19 November 2007

Ferring Pharmaceuticals presented the results of a cost-utility study supporting the adoption of Euflexxa (1% sodium hyaluronate) intra-articular hyaluronic acid for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Ferring Pharmaceuticals

Go to company listing

Related Drugs

Healon

Sodium Hyaluronate

Hyalgan

Hyaluronate

Provisc

Go to drug listing